Iradimed vs Neuropace
Neuropace is the larger business, with $100.0m of revenue in fiscal 2025 against $83.8m for Iradimed (1.2 times as much). Neuropace grew faster (25.1% against 14.4%). Iradimed kept more of each dollar of sales as profit: a net margin of 26.8% against -21.5%. Iradimed carries less debt relative to equity (0.0% against 309.4%).
| Latest fiscal year | IradimedIRMD, 2025 | NeuropaceNPCE, 2025 |
|---|---|---|
| Revenue | $83.8m | $100.0m |
| Revenue growth | 14.4% | 25.1% |
| Net income | $22.5m | −$21.5m |
| Operating margin | 31.2% | -16.3% |
| Net margin | 26.8% | -21.5% |
| Return on equity | 24.8% | -158.7% |
| Free cash flow | $17.2m | −$11.3m |
| Cash | $51.2m | $21.7m |
| Total debt | $0 | $58.9m |
| Debt to equity | 0.0% | 309.4% |
| Dividend per share | — | — |
| Dividend yield | 1.6% | — |
| Share buybacks | — | $49.5m |
| Employees | — | 209 |
| Market value | $1.02bn | $423m |
| Price vs our value range | Above our value range | — |
| Moat score | 81 (Strong) | 37 (Weak) |
| Insider trades, 12 months | 0 buys, 116 sales | 0 buys, 1 sales |